Analysts expect Inovio Pharmaceuticals Inc (NASDAQ:INO) to announce $2.63 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest sales estimate coming in at $4.15 million and the lowest estimate coming in at $1.10 million. Inovio Pharmaceuticals posted sales of $2.65 million during the same quarter last year, which suggests a negative year over year growth rate of 0.8%. The business is expected to issue its next quarterly earnings report on Wednesday, November 14th.
On average, analysts expect that Inovio Pharmaceuticals will report full-year sales of $31.69 million for the current financial year, with estimates ranging from $28.10 million to $35.28 million. For the next year, analysts anticipate that the business will report sales of $16.90 million per share, with estimates ranging from $4.20 million to $29.60 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.22). The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $7.50 million. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. During the same quarter in the prior year, the business posted ($0.31) earnings per share.
A number of brokerages recently issued reports on INO. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, June 28th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Maxim Group set a $8.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 10th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $11.25.
In other Inovio Pharmaceuticals news, CFO Peter Kies sold 35,000 shares of the company’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $4.44, for a total transaction of $155,400.00. Following the transaction, the chief financial officer now directly owns 97,088 shares in the company, valued at approximately $431,070.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.40% of the company’s stock.
Several hedge funds have recently made changes to their positions in INO. ARK Investment Management LLC increased its stake in Inovio Pharmaceuticals by 79.8% during the 2nd quarter. ARK Investment Management LLC now owns 1,194,657 shares of the biopharmaceutical company’s stock worth $4,683,000 after purchasing an additional 530,247 shares in the last quarter. Guggenheim Capital LLC bought a new stake in Inovio Pharmaceuticals during the 1st quarter worth approximately $2,375,000. Renaissance Technologies LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter worth approximately $1,503,000. BlackRock Inc. increased its stake in Inovio Pharmaceuticals by 5.5% during the 2nd quarter. BlackRock Inc. now owns 6,845,338 shares of the biopharmaceutical company’s stock worth $26,834,000 after purchasing an additional 356,105 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Inovio Pharmaceuticals by 247.7% during the 4th quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock worth $1,856,000 after purchasing an additional 320,376 shares in the last quarter. 32.56% of the stock is owned by institutional investors.
Inovio Pharmaceuticals traded up $0.10, reaching $4.46, during trading on Tuesday, according to Marketbeat Ratings. The company’s stock had a trading volume of 416,780 shares, compared to its average volume of 682,208. The stock has a market capitalization of $398.93 million, a PE ratio of -4.09 and a beta of 1.67. Inovio Pharmaceuticals has a 1-year low of $3.64 and a 1-year high of $7.00.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.